Who is the CEO of Accretion Nutraveda Ltd?
- Answer Field
-
Mr. Mayur Sojitra is the Managing Director and Promoter of Accretion Nutraveda Ltd.
Accretion Nutraveda Limited is a healthcare-focused manufacturing company engaged in the production of ayurvedic and nutraceutical products across various dosage forms, including tablets, capsules, liquids, powders, oils, and external applications. Operating as a Contract Development and Manufacturing Organisation (CDMO), the company serves clients in domestic and select international markets. Its product portfolio covers multiple healthcare categories such as liver care, women’s health, bone and joint care, digestive care, respiratory care, cognitive support, paediatric nutrition, and skin and hair care. The company operates from a GMP-compliant manufacturing facility in Gujarat, supported by recognised quality and safety certifications, which enables it to undertake regulated manufacturing for different client requirements.
To apply for the Accretion Nutraveda IPO, an investor needs an active Demat account, a trading account, and a bank account linked for online payments. The application can be submitted through the ASBA facility available on net banking platforms or via supported online trading applications. After selecting the IPO, investors need to enter the bid details and confirm the application. The amount remains blocked until the allotment process is completed, after which shares are credited to the Demat account if allotted.
For more details, visit the Accretion Nutraveda Limited IPO page.
Details | Information |
IPO Date | January 27, 2026 to January 30, 2026 |
Issue Size | 19,20,000 shares (agg. up to ₹25 Cr) |
Price Band | ₹122 to ₹129 per share |
Lot Size | 1000 shares |
Listing At | BSE SME |
Purchase of machineries for automation in company’s existing manufacturing unit
Purchase of machineries for a new manufacturing setup
Funding working capital requirements of the company
General corporate purposes
Event | Date |
IPO Open Date | Tue, Jan 27, 2026 |
IPO Close Date | Fri, Jan 30, 2026 |
Tentative Allotment | Mon, Feb 2, 2026 |
Initiation of Refunds | Tue, Feb 3, 2026 |
Credit of Shares to Demat | Tue, Feb 3, 2026 |
Tentative Listing Date | Wed, Feb 4, 2026 |
Cut-off time for UPI mandate confirmation | 5 PM on Fri, Jan 30, 2026 |
₹122 to ₹129 per share
Application | Lots | Shares | Amount |
Individual investors (Retail) (Min) | 2 | 2,000 | ₹2,58,000 |
Individual investors (Retail) (Max) | 2 | 2,000 | ₹2,58,000 |
S-HNI (Min) | 3 | 3,000 | ₹3,87,000 |
S-HNI (Max) | 7 | 7,000 | ₹9,03,000 |
B-HNI (Min) | 8 | 8,000 | ₹10,32,000 |
The Accretion Nutraveda Limited IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:
Access your trading account using the broker's app or website.
Go to the IPO section to view active IPO listings.
Locate Accretion Nutraveda Limited IPO in the list of available IPOs and click the ‘Apply’ button.
Specify the number of shares (lot size: 1000 shares) within the price band of ₹122 to ₹129 per share.
Enter your UPI ID for payment authorisation and ensure sufficient funds in your bank account.
Review your application details and confirm the UPI mandate before 5 PM on the last application day.
Submit the application and monitor the allotment status to check if shares have been allocated to you.
The allocation of shares in the Accretion Nutraveda IPO is structured across investor categories in line with applicable regulatory requirements. The issue provides defined reservations for qualified institutional buyers, non-institutional investors, and retail individual investors, with each category allotted a specified proportion of the net issue. This allocation framework outlines how the shares offered are distributed among different classes of investors.
Investor Category | Shares Offered |
Market Maker Shares Offered | 96,000 (5.00%) |
QIB Shares Offered | 9,08,000 (47.29%) |
NII (HNI) Shares Offered | 2,76,000 (14.37%) |
Retail Shares Offered | 6,40,000 (33.33%) |
Total Shares Offered | 19,20,000 (100.00%) |
This reservation structure reflects the categorisation and allocation approach disclosed for the issue, indicating the proportion of shares available to each investor segment.
Total Assets: Grew from ₹4.06 crore in FY23 to ₹10.86 crore as of March 2025.
Total income: Reached ₹16.06 crore in March 2025, as compared to ₹3.07 crore in FY23.
Profit After Tax (PAT): Stood at ₹2.61 crore for March 2025 as compared to ₹0.28 crore in FY23.
Net Worth: Recorded at ₹5.35 crore in March 2025 in comparison to ₹0.26 crore in FY23.
Reserves and surplus: Stood at ₹4.86 crore in March 2025, as compared to ₹-0.10 crore in FY23.
EBITDA: Stood at ₹3.65 crore in March 2025 in comparison to ₹0.59 crore in FY23.
The company has expanded its asset base over recent financial periods, reflecting a broader operational scale and increased business activity.
Income levels have shown steady improvement, indicating higher business volumes and wider client engagement across its manufacturing services.
Profitability has strengthened compared to earlier years, supported by improved utilisation of manufacturing capacity and operational efficiencies.
The company’s net worth has increased, mainly due to retained earnings and internal accruals generated from business operations.
Reserves and surplus have moved to a positive position, reflecting improved financial stability and better capital retention.
Operating performance has improved in line with higher production and sales activity, contributing to better cost absorption.
The overall financial trend indicates gradual strengthening of the balance sheet and operating profile, supported by expansion in manufacturing activities and client servicing.
The company operates largely as a contract manufacturer, which may result in dependence on client orders and continued business relationships for revenue visibility.
Operations are concentrated in a single manufacturing facility, which may expose the business to operational disruptions arising from regulatory, logistical, or facility-related issues.
The planned use of IPO proceeds for automation and new manufacturing capacity may support expansion of production capabilities and wider client engagement over time.
The company’s presence across ayurvedic and nutraceutical segments, along with domestic and export markets, provides scope to cater to varied healthcare manufacturing requirements as demand for such products continues to evolve.
KPI | Mar 31, 2025 |
ROE | 81.22% |
ROCE | 36.98% |
Debt/Equity | 0.72 |
RoNW | 48.85% |
PAT Margin | 16.33% |
EBITDA Margin | 22.79% |
Price to Book Value | 8.76 |
Registrar | Lead Manager(s) |
Kfin Technologies Ltd. | Sobhagya Capital Options Pvt.Ltd. |
Accretion Nutraveda Ltd. 27 Xcelon Industrial Park-1 Vasna-Chacharwadi, TaSanand, Ahmedabad, Gujarat, 382213
Phone: +91- 9904366177
Email: compliance@accretionnutraveda.com
Website: https://accretionnutraveda.com/
Accretion Nutraveda Limited operates as a contract manufacturer in the ayurvedic and nutraceutical segments, with a product portfolio covering multiple healthcare categories and manufacturing activities supported by recognised certifications. The IPO outlines defined objectives related to capacity expansion, automation, and working capital requirements, as disclosed in the offer details.
The IPO application process follows a standard online route through ASBA or supported trading platforms and requires a Demat account with a linked bank account. Investors may review the issue schedule, pricing, allocation structure, and disclosed risks before submitting an application within the specified timeline.
Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Accretion Nutraveda IPO allotment status.
No result found
Mr. Mayur Sojitra is the Managing Director and Promoter of Accretion Nutraveda Ltd.
The Accretion Nutraveda IPO is scheduled to open for subscription on January 27, 2026, and will close on January 30, 2026, as per the disclosed IPO timeline.
Accretion Nutraveda Limited operates as a Contract Development and Manufacturing Organisation (CDMO) in the ayurvedic and nutraceutical segments. The company manufactures products across multiple dosage forms for domestic and international clients. The sustainability of its business model depends on continued client relationships, regulatory compliance, and the company’s ability to maintain manufacturing quality standards over time.
The IPO comprises 19,20,000 equity shares, aggregating up to ₹25 crore, as disclosed in the issue details. The shares are proposed to be listed on the BSE SME platform.
The pre-apply facility allows investors to submit their IPO application before the official opening date. The application is submitted in advance, and the UPI mandate is authorised once the IPO opens for subscription.
The lot size for the Accretion Nutraveda IPO is 1,000 shares. Retail investors are required to apply for a minimum of two lots, which equals 2,000 shares, as per the disclosed application details.
The tentative allotment date for the Accretion Nutraveda IPO is February 2, 2026, based on the IPO schedule provided in the issue timeline.
Kfin Technologies Ltd. has been appointed as the registrar for the Accretion Nutraveda IPO.
There are no publicly stated governance issues or red flags highlighted. Investors may review the offer documents, including sections on management, board composition, and risk factors, for detailed and verified disclosures.
Investors can apply for the IPO through the ASBA facility using net banking or through supported online trading platforms. The process involves selecting the IPO, entering bid details within the prescribed lot size, providing a UPI ID for payment authorisation, and confirming the mandate before the cut-off time on the closing day.
Yes, a Demat account is required to apply for the Accretion Nutraveda IPO, as shares are credited electronically to the investor’s Demat account upon allotment.
Investors can check the allotment status through the registrar’s website or the stock exchange portal once the allotment is finalised. If shares are allotted, they will be credited to the Demat account, and if not, the blocked amount will be released as per the refund timeline.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading